Back

Validation and testing of an in vitro model to study medical treatments for anterior urethral stricture disease: assessing the potential efficacy of phosphodiesterase-4 (PDE4) inhibition and testosterone

Lozano, L. P.; Volk, M. J.; Miller, C. D.; Berg, J. E.; Allamargot, C.; Schlaepfer, C. H.; Kurtzman, J. T.; Christensen, M. B.; Myers, J. B.; Hertz, A. M.; Swanton, A. R.; Tucker, B. A.; Erickson, B. A.

2026-05-17 pharmacology and toxicology
10.64898/2026.05.13.724950 bioRxiv
Show abstract

ObjectiveTo 1) determine the expression and distribution of all PDE4 isozymes (A-D) along the length of the anterior urethra, 2) culture fibroblasts and epithelial cells from healthy and strictured urethras, 3) investigate an in vitro model of anterior urethral stricture disease (aUSD), and 4) assess the therapeutic potential of phosphodiesterase-4 (PDE4) inhibitors and testosterone compared to paclitaxel. MethodsThe presence and relative abundance of PDE4 isozymes (A-D) was confirmed using immunohistochemistry on 5 male cadaveric urethras. Human urethral fibroblasts (FBs) were cultured from healthy control urethras of patients undergoing vaginoplasty (n=3) and from idiopathic bulbar urethral strictures (L2S1E2) of patients undergoing urethroplasty (n=3). Epithelial cells (ECs) were cultured from a healthy control urethra and two urethral strictures. To investigate a model of aUSD, Control FBs were stimulated with TGF{beta}1 and compared to Stricture FBs on assays of cell proliferation and expression of genes relevant to aUSD pathophysiology. To test therapeutics, Stricture FBs were treated with the PDE4 inhibitor, roflumilast, testosterone (T), or paclitaxel and compared to Control FBs on the previously mentioned assays and cell viability. ResultsPDE4- A, B, and D were detected along the length of the urethra. Expression levels did not differ between urethral regions. TGF{beta}1 altered proliferation and gene expression in a dose-dependent manner. Roflumilast and T preserved cell viability and proliferation and decreased expression of genes positively associated with auSD. ConclusionUrethral FBs and ECs can be cultured from healthy and strictured surgical specimens, enabling in vitro research. PDE4 inhibitors and T may be non-cytotoxic alternatives or additions to paclitaxel for aUSD. HighlightsO_LIPDE4 isozymes A, B, and D are expressed in adult anterior urethras C_LIO_LIPDE4 is expressed equally from proximal bulbar to meatal urethra C_LIO_LIEpithelial cells and fibroblasts can be cultured from healthy and stricture urethra C_LIO_LITGF{beta}1 may not be an optimal method to model aUSD in vitro C_LIO_LIUnlike paclitaxel, roflumilast and testosterone are not toxic to urethral cells C_LI

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 0.7%
42.1%
2
Scientific Reports
3102 papers in training set
Top 12%
7.3%
3
Frontiers in Pharmacology
100 papers in training set
Top 0.3%
6.8%
50% of probability mass above
4
Journal of Clinical Medicine
91 papers in training set
Top 0.6%
5.2%
5
Journal of Translational Medicine
46 papers in training set
Top 0.1%
3.8%
6
Molecular Human Reproduction
11 papers in training set
Top 0.1%
1.8%
7
ACS Omega
90 papers in training set
Top 2%
1.6%
8
International Journal of Environmental Research and Public Health
124 papers in training set
Top 5%
1.3%
9
BMJ Public Health
18 papers in training set
Top 0.3%
1.3%
10
Toxicological Sciences
38 papers in training set
Top 0.4%
1.0%
11
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 4%
1.0%
12
Frontiers in Veterinary Science
30 papers in training set
Top 0.6%
1.0%
13
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.8%
0.8%
14
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.3%
0.8%
15
Pharmacology Research & Perspectives
11 papers in training set
Top 0.3%
0.7%
16
The Journal of Steroid Biochemistry and Molecular Biology
10 papers in training set
Top 0.4%
0.7%
17
American Journal of Physiology-Renal Physiology
25 papers in training set
Top 0.3%
0.7%
18
JCI Insight
241 papers in training set
Top 9%
0.5%
19
Cancers
200 papers in training set
Top 5%
0.5%
20
Translational Vision Science & Technology
35 papers in training set
Top 0.6%
0.5%
21
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.5%
22
Biomedicines
66 papers in training set
Top 4%
0.5%
23
British Journal of Pharmacology
34 papers in training set
Top 0.8%
0.5%
24
BMC Molecular and Cell Biology
14 papers in training set
Top 0.2%
0.5%